Table 1.
Summary of each injecting-related cohort, and outcomes/exposures used to assess HIV test uptake in Glasgow
| Injecting-related cohort | Description | Outcomes and exposures |
|---|---|---|
| (1) Needle exchange surveillance initiative (NESI) cohort | Study design | Primary outcome |
| Repeated cross-sectional bio-behavioural survey | Self-report of HIV test in the last year (yes/no) | |
| Population | Primary exposure | |
| Ever or injected drugs in the last 6 months | Time period (pre-outbreak, 2010–2014/early outbreak, 2015–2016/ongoing outbreak, 2017–2019) | |
| Setting | Secondary exposures | |
| Harm reduction sites (including drug treatment and needle exchange) | Local authority regiona (Glasgow city/rest of Glasgow) | |
| Data source | Age (< 35/35–45/46 +) | |
| Needle Exchange Surveillance Initiative (NESI) | Sex (male/female) | |
| Time period | Self-report of prescribed methadone (not prescribed/in the last 6 months/in the past but not the last 6 months) | |
| 2010–2019 | ||
| (2) OAT cohort | Study design | Primary outcome |
| Retrospective cohort study constructed using data linkage | HIV test in the last yearc (yes/no) | |
| Population | Primary exposure | |
| People prescribed OATb | Time period (pre-outbreak, 2010–2014/early outbreak, 2015–2016/ongoing outbreak, 2017–2019/COVID-19, 2020-June 2021) | |
| Setting | Secondary exposures | |
| Drug treatment services | Local authority region (Glasgow city/rest of Glasgow) | |
| Data sources | Age (< 35/35–45/46 +) | |
| Laboratory HIV test data linked to the Prescribing Information System record of all individuals who received OAT | Sex (male/female) | |
| Time period | Injecting-related hospital admission in the last 2 years (yes/no) | |
| 2010–June 2021 | ||
| (3) Injecting-related hospital admission (IRHA) cohort | Method | Primary outcome |
| Retrospective cohort study constructed using data linkage | HIV test in the last yearc (yes/no) | |
| Population | Primary exposure: | |
| People hospitalised for an injecting-related hospital admissiond | Time period (pre-outbreak, 2010–2014/early outbreak, 2015–2016/ongoing outbreak, 2017–2019/COVID-19, 2020-June 2021) | |
| Setting | Secondary exposures: | |
| Secondary care | Local authority region (Glasgow city/rest of Glasgow) | |
| Data source | Age (< 35/35–45/46 +) | |
| Laboratory HIV test data linked to the Scottish Mortality Record 01 record of all individuals who have been hospitalised for an injecting-related hospital admissiond | Sex (male/female) | |
| Time period | Prescribed OAT (not prescribed/in the last 6 months/in the past but not the last 6 months) | |
| 2010–June 2021 |
NESI Needle Exchange Surveillance Initiative, OAT Opioid agonist therapy, IRHA Injecting-related hospital admission
aBased on region of recruitment in the NESI study
bPrescribed methadone, buprenorphine and buprenorphine/naloxone
cLaboratory record of an HIV test in the last year, relative to last OAT prescription date or to last IRHA date for each respective calendar period
dInjecting-related hospital defined used ICD-10 codes included in Appendix, Table 4